证券代码：002581 证券简称：ST未名 公告编号：2025-081 山东未名生物医药股份有限公司 关于召开 2025 年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025年第三次临时股东会 2、股东会的召集人：公司董事会 3、会议召开的合法、合规性：公司2025年第三次临时股东会会议的召集、 召开符合《公司法》等法律、法规、规范性文件和《公司章程》的有关规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2025年12月3日下午2:30 （2）网络投票时间： ①通过深圳证券交易所交易系统进行投票的时间：2025年12月3日上午 9:15-9:25，9:30-11:30，下午1:00-3:00； ②通过互联网投票系统进行网络投票的时间：2025年12月3日9:15-15:00。 5、会议的召开方式：本次股东会采用现场表决与网络投票相结合的方式召 开。 6、会议的股权登记日：2025年11月28日 7、出席对象： （1）截止2025年11月28日下午3:00收市后，在中国证券登记结 ...

证券代码：002581 证券简称：ST未名 公告编号：2025-082 山东未名生物医药股份有限公司 第六届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东未名生物医药股份有限公司(以下简称"公司")第六届董事会第九次会 议于 2025 年 11 月 17 日上午 10 时以通讯方式召开。应参加表决董事 11 名，实际 参加表决董事 11 人，分别为：岳家霖、刘文俊、徐隽雄、周婷、陈星、史晓如、 黄桂源、蔡艳红、张荣富、杨军、夏阳。董事会会议通知已于 2025 年 11 月 15 日 以通讯方式发出，会议由公司董事长岳家霖先生主持。本次董事会的召集和召开 符合国家有关法律法规、《董事会议事规则》及《公司章程》的规定。本次会议 审议了如下议案： 二、董事会会议审议情况 （一）审议通过了《关于拟变更会计师事务所的议案》 经综合考虑公司业务发展情况和整体审计的需要，拟变更会计师事务所，拟 聘任和信会计师事务所（特殊普通合伙）为公司 2025 年度审计机构，聘期一年， 提请公司股东会审议本议案并授权公司经营管理层 ...

Group 1 - ST Unimed (SZ 002581) announced on November 17 that its sixth board meeting was held via telecommunication to discuss the proposal for changing the accounting firm [1] - For the first half of 2025, ST Unimed's revenue is entirely derived from its pharmaceutical business segment, accounting for 100.0% [1] - As of the report date, ST Unimed has a market capitalization of 5.5 billion yuan [2]

Core Viewpoint - The company has obtained a pharmaceutical business license for its wholly-owned subsidiary, Shandong Weiming Tianan Pharmaceutical Co., Ltd., allowing it to operate in various pharmaceutical sectors [1] Group 1 - The license was issued by the Shandong Provincial Drug Administration [1] - The approved business scope includes traditional Chinese medicine pieces, Chinese patent medicines, chemical drugs, and biological products (excluding vaccines) [1] - The license also covers the operation of refrigerated and frozen pharmaceuticals [1]

证券代码：002581 证券简称：ST未名 公告编号：2025-080 山东未名生物医药股份有限公司 关于拟变更会计师事务所的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、山东未名生物医药股份有限公司(以下简称"公司")2024 年度财务审计 报告的审计意见类型为带强调事项段保留意见。 2、拟聘任的会计师事务所名称：和信会计师事务所（特殊普通合伙）（以 下简称"和信会计师事务所"）。 3、原聘任的会计师事务所名称：深圳广深会计师事务所（普通合伙）。 4、变更会计师事务所的原因及前任会计师的异议情况：根据公司业务现状 及发展需要，公司拟聘请和信会计师事务所为公司 2025 年度审计机构。公司已 就变更会计师事务所的相关事宜与前后任会计师事务所进行了沟通说明，前后任 会计师事务所均已知悉本事项且对本次更换无异议。 5、本次拟变更会计师事务所符合财政部、国务院国资委、证监会印发的《国 有企业、上市公司选聘会计师事务所管理办法》（财会〔2023〕4 号）的规定。 6、公司审计委员会、董事会对本次拟更换会计师事务所事项无异议。本事 项尚需提交公 ...

企业名称：山东未名天安医药有限公司 证券代码：002581 证券简称：ST未名 公告编号：2025-083 山东未名生物医药股份有限公司 关于全资子公司取得药品经营许可证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 山东未名生物医药股份有限公司（以下简称"公司"）全资子公司山东未名 天安医药有限公司（以下简称"未名天安"）于近日取得了由山东省药品监督管 理局颁发的《药品经营许可证》，现将有关信息公告如下： 一、基本情况 社会信用代码：91370303MAC6B1LN9W 许可证编号：鲁 AA533000653 经营方式：批发（法人） 许可范围：中药饮片，中成药，化学药，生物制品（除疫苗），以上经营范 围含冷藏冷冻药品。 注册地址：山东省淄博市张店区马尚街道办事处心环东路与荣二路交汇处齐 美大厦 27 层 2711 房间 法定代表人：常为民 主要负责人：常为民 质量负责人：贾静 全资子公司未名天安取得《药品经营许可证》，标志着其具备了依法从事药 品批发与流通业务的资格，有助于完善公司在医药产业链的布局，为公司拓展药 品销售渠道、提升供应链协同效率提供 ...

Group 1 - Company plans to raise no more than 3.6 billion yuan through a private placement to fund seven projects, including a 500,000 kW green power project in Inner Mongolia [1] - Company has received acceptance for a clinical trial application for its self-developed drug for metastatic pancreatic ductal adenocarcinoma [1] - Company intends to establish a joint venture to implement a high-quality gallium arsenide chip construction project with a total investment of 272 million yuan [2] Group 2 - Company reported a revenue of 142 million yuan from pig sales in October, with a total sales volume of 162,800 pigs [3] - Company signed an annual procurement contract to supply 870,000 tons of electrolyte products from 2026 to 2028 [5] - Company plans to reduce its shareholding by up to 3% through various trading methods [7] Group 3 - Company intends to purchase 100 hydrogen fuel cell vehicles for a total price of 78.32 million yuan [9] - Company plans to acquire a 51% stake in a semiconductor equipment company for 510 million yuan [10] - Company has regained eligibility to participate in military procurement activities after being removed from the banned list [12] Group 4 - Company plans to establish a joint venture with state-owned funds for rural development with a total registered capital of 2.87 billion yuan [14] - Company reported a revenue of 1.918 billion yuan from pig sales in October, with a significant year-on-year increase [16][17] - Company plans to distribute a cash dividend of 0.01 yuan per share, totaling 7.9801 million yuan [18] Group 5 - Company has submitted an application for H-share listing on the Hong Kong Stock Exchange [19] - Company received approval for its convertible bond issuance application [20] - Company plans to establish a wholly-owned subsidiary with an investment of 70 million yuan focused on innovative medical research [22] Group 6 - Company reported a 33.87% year-on-year increase in sales volume for October [26] - Company has received a product designation from a leading new energy vehicle brand, with an expected total revenue of approximately 470 million yuan [28] - Company has initiated a key Phase III clinical trial for an innovative eye drop treatment for moderate to severe dry eye syndrome [30] Group 7 - Company reported a total automobile sales volume of 170,700 units in October, a year-on-year decrease of 8.1% [30] - Company plans to invest 16 million USD in establishing a production base in Vietnam [33] - Company has received a warning letter from the regulatory authority due to a breach of commitment by its controlling shareholder [52]

Core Viewpoint - The biopharmaceutical sector experienced a decline of 0.37% on November 7, with He Yuan Bio leading the drop. The Shanghai Composite Index closed at 3997.56, down 0.25%, while the Shenzhen Component Index closed at 13404.06, down 0.36% [1]. Group 1: Stock Performance - Wan Ze Co. (000534) saw a significant increase in stock price, closing at 22.51 with an 8.80% rise and a trading volume of 754,200 shares, amounting to 1.681 billion yuan [1]. - Tibet Pharmaceutical (600211) closed at 46.05, up 2.74%, with a trading volume of 80,600 shares, totaling 371 million yuan [1]. - Anke Bio (300009) increased by 2.25%, closing at 10.93 with a trading volume of 442,300 shares, amounting to 482 million yuan [1]. - The overall biopharmaceutical sector saw a net outflow of 678 million yuan from institutional investors, while retail investors had a net inflow of 304 million yuan [2][3]. Group 2: Capital Flow - The main capital inflow was observed in Tibet Pharmaceutical, with a net inflow of 26.13 million yuan from institutional investors, while retail investors had a net outflow of 36.64 million yuan [3]. - Anke Bio also experienced a net inflow of 23.91 million yuan from institutional investors, with retail investors seeing a net outflow of 13.09 million yuan [3]. - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with institutional investors pulling back while retail investors showed some interest [2][3].

Core Viewpoint - The domestic first eye drop formulation containing recombinant human nerve growth factor, SMR001, is advancing towards market launch, with recent approval for its Phase III clinical trial aimed at treating moderate to severe dry eye disease [1][2]. Group 1: Product Development - ST Unimed's subsidiary, Shandong Yandu Biotechnology Co., has developed SMR001 eye drops, which are the first in China to use recombinant human nerve growth factor as an active ingredient [1][2]. - The product aims to repair damaged corneal nerves and promote epithelial regeneration, potentially offering a new treatment option for moderate to severe dry eye disease [1][2]. Group 2: Market Potential - The prevalence of dry eye disease globally ranges from 5% to 50%, with China reporting a rate of approximately 21% to 30%, indicating a significant public health issue [1]. - The incidence of dry eye among the 18-35 age group in China has reached 63%, a 400% increase over the past decade, driving growth in the pharmaceutical market [2]. - The Chinese ophthalmic drug market is projected to reach 44 billion yuan by 2025 and 108.4 billion yuan by 2030, with the dry eye drug segment expected to grow to 4.79 billion yuan in 2024, reflecting a compound annual growth rate of 16.17% from 2020 to 2024 [2]. Group 3: Clinical Trial Progress - SMR001 eye drops received a clinical trial notification on May 25, 2020, completed Phase I trials by February 26, 2022, and has shown effectiveness in treating moderate to severe dry eye disease in Phase II trials [3]. - The recent approval for the Phase III clinical trial marks a significant step in validating the efficacy and safety of SMR001 for patients with moderate to severe dry eye disease [3].

Core Viewpoint - ST Unimed (002581.SZ) announced that its wholly-owned subsidiary, Shandong Yandu Biotechnology Co., Ltd., has received ethical approval for the Phase III clinical trial of its innovative drug, recombinant human nerve growth factor SMR001 eye drops, for the treatment of moderate to severe dry eye syndrome [1] Summary by Categories Clinical Development - The ethical approval from the Ethics Committee of Beijing Tongren Hospital, affiliated with Capital Medical University, allows the project to officially commence [1] - The approval signifies that the project has a compliant ethical foundation for conducting clinical trials [1] Financial Impact - The short-term impact on the company's operating performance is not expected to be significant due to the nature of the clinical trial approval [1]